Method of administering azithromycin

Patent 5605889 Issued on February 25, 1997. Estimated Expiration Date:

April 29, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
Patent #: 4382085
Issued on: 05/03/1983
Inventor: Sciavolino , et al.

N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
Patent #: 4474768
Issued on: 10/02/1984
Inventor: Bright

11-Methyl-11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl-7,1 3,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one and derivatives thereof
Patent #: 4517359
Issued on: 05/14/1985
Inventor: Kobrehel , et al.

Azithromycin and derivatives as antiprotozoal agents
Patent #: 4963531
Issued on: 10/16/1990
Inventor: Remington

O-methyl derivatives of azithromycin A
Patent #: 5250518
Issued on: 10/05/1993
Inventor: Kobrehel, et al.

2'-position modified compound of erythromycin or its derivative Patent #: 5350839
Issued on: 09/27/1994
Inventor: Asaka, et al.

Inventors

Application

No. 235069 filed on 04/29/1994

US Classes:

514/29, The hetero ring has exactly 13 ring carbons (e.g., erythromycin, etc.)424/464, Tablets, lozenges, or pills424/465, With claimed perfecting feature in contents (e.g., excipient, lubricant, etc.)424/474, Coated pills or tablets424/480, Cellulose or derivative424/481, Containing natural gums or resins514/960, SIGNIFICANT, TABLET FORMULATION (E.G., DESIGNATED EXCIPIENT, DISINTEGRANT, GLYDENT OR LUBRICANT, ETC.)536/7.2Erythromycin or derivative (e.g., oleandomycin, etc.)

Examiners

Primary: Kight, John
Assistant: Lee, Howard C.

Attorney, Agent or Firm

Richardson; Peter C., Benson; Gregg C., Jones; James T.

Foreign Patent References

0307128 EP. 03/13/1989
0582396 EP. 02/13/1994

International Classes

A61K 031/70
A61K 009/14
A61K 009/20

Abstract

An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And therapeutic packages containing the dosage forms.

Other References

Curatolo et al. J. Pharm. Sci., vol. 77 (4), pp. 322-324, (1988)
Welling et al. J. Pharm. Sci., vol. 67 (6), pp. 764-766, (1978)
Welling et al. J. Pharm. Sci., vol. 68 (2), pp. 150-155, (1979)
Malmborg, A. Curr. Med. Res. Opin. vol. 5 (Suppl. 2), pp. 15-18, (1978)
Drew et al., Pharmacotherapy, 12, 3, 161-173 (1992)
Chu et al., J. Clin. Pharmacol., 32, 32-36 (1992)
Hopkins, S., Am. J. Med., 91 (Suppl 3A), 405-455 (1991)
Toothaker et al., Ann. Rev. Pharmacol. Toxicol. vol. 20, 173-199, 1980
Russell et al., Pharmaceutical Research, vol. 10, No. 2, 187-196, 1993
CA Abstracts: vol. 120:38194a; 1994
Zithromax (Trademark of Pfizer, Inc.) Capsules Package Insert for azithromycin capsule dosage form sold commercially in U.